A correlation between LP-PLA2 and monocyte levels in atherosclerosis risk subjects

Cover Page

Cite item

Abstract

Background. Cardiovascular disease (CVD) is the most significant cause of death worldwide. More than 17.9 million people died from CVD, of which 85% deceased due to heart disease. On the other hand, atherosclerosis is one of the most dominant CVD in most developing countries and developed countries. Lp-PLA2 is an enzyme produced by inflammatory cells and a pro-atherogenic protein in atherosclerosis. In the process, monocytes will produce Lp-PLA2 so that it may hydrolyse oxidized low density lipoprotein (oxLDL) into lysophosphatidylcholine (lysoPC) and oxidized fatty acids (oxFA), atherogenic proteins involved in atherogenesis. A chronic inflammatory process that occurs in atherosclerosis requires early detection to avoid CVD severity. The research aims to determine the correlation between Lp-PLA2 concentration and monocyte count as well as percentage in cohorts linked to risk of atherosclerosis. Materials and methods. This study was a descriptive correlational analysis of the population with conditions at risk of atherosclerosis. The total number of respondents sampled in this research was 86. We used the ELISA method to measure Lp-PLA2 concentration and the Hematology Analyzer method to measure monocyte count and percentage. Results. The relationship between monocyte and Lp-PLA2 level accounts for a probability value of 0.028. The correlation coefficient of 0.789 is categorized as very strong. Conclusion. Increase in the concentration of Lp-PLA2 correlates with monocyte count and percentage in a population with conditions at risk of atherosclerosis.

Full Text

Introduction

Cardiovascular disease (CVD) is the most significant cause of death worldwide. More than 17.9 million people died from CVD, 31% of all deaths in the world, of which 85% globally were due to heart disease [33]. On the other hand, atherosclerosis is one of the most dominant CVD in most developing countries and developed countries. Therefore, a high mortality rate has been registered with this disease. Most Asian countries experience challenges from cardiovascular disease, with mortality rates varying from 103 to 366 per year in adults reported by newly published studies. Elevated cholesterol levels in the population have become a frequent cause. Older men and people with dyslipidemia, hypertension, and diabetes are at high risk of cardiovascular disease. Over the past decade, there has been a tendency to escalate atherosclerotic charges, especially in East Asia, with an increase of 117.2% and 115.3% of total deaths and disability-adjusted by 2015 [7].

Many CVD risk factors (smoking, dyslipidemia, hypertension) are known to lead to atherosclerosis. It begins with dysfunction of endothelial function. Endothelial function plays a central role in vasomotor abnormalities and inflammatory responses [8]. Dysfunction of these tissues happens due to inflammatory response followed by plaque formation. Plaque consists of cholesterol, fatty acid, calcium, and fibrin, leading to blockage at the artery wall. Blockage of the artery wall by the plaque will reduce the flow of blood and oxygen supply [16]. The abrupt change mechanism is associated with acute thrombosis in atherosclerotic plaque that is eroded, cracked or ruptured. The rupture of atherosclerotic plaque is associated with unstable atherosclerotic plaque changes that are volatile and easily torn. Therefore, laboratory tests are also intended to detect early plaque phase changes before arterial plaque rupture [1, 14].

Arterial plaque rupture will cause a lesion that will attract circulating monocytes to the lesion area [17]. The interaction between leukocytes, platelets, and blood vessel cells leads to monocyte production in the bone marrow, releasing it into an artery and attaching it to the endothelial cell. Continuous recruitment of monocytes to the lesion will cause the accumulation of macrophages. Macrophages will ingest oxidised lipoprotein into developing plaques through scavenger receptors [29]. In this process, macrophages cause the expansion of the necrotic nucleus of atherosclerotic plaque, fibrous capsule depletion, and destabilisation of plaque resulting in rupture of arterial plaque, which will initiate atherosclerosis [9].

Many endogenous factors affect the occurrence of atherosclerosis, both protective factors and aggravating factors. Monocytes are a type of protective cell, but they also play a role in induction of atherosclerosis. Monocytes are white blood cells related to granulocytes, which are white blood cells designed to kill bacteria. Monocytes are produced in the bone marrow and then released into the bloodstream. Young monocyte cells start as monoblasts in the bone marrow. Once released, they leave the bone marrow and circulate through the bloodstream for a few hours before getting to other tissues, such as the spleen and lungs. Once monocytes are embedded in tissues, they become macrophages. Macrophages support healthy immune function by destroying and ingesting pathogens. They also help lymphocyte cells recognise pathogens and create antibodies against them [12, 13]. Rupture at the blood vessel will cause a lesion, attracting the circulating monocytes to the lesion area. The interaction between leukocytes, platelets, and blood vessel cells leads to monocyte production in the bone marrow and release to circulating blood. Continuous recruitment of monocyte to the lesion will cause the accumulation of macrophages. Macrophages ingest oxidised lipoproteins through scavenger receptors and lipid-rich cells, contributing to the physical aspect of plaque development [21].

In this process, macrophages, lymphocytes and mast cells produce an enzyme known as Lipoprotein-associated phospholipase A2 (Lp-PLA2) [32]. Lp-PLA2 hydrolyses oxidised LDL (oxLDL) to produce lysophosphatidylcholine (lysoPC) and oxidised fatty acids (oxFA). LysoPC and oxFA will cause endothelial dysfunction, inducing apoptosis of smooth muscle cells and macrophages that cause the expansion of the necrotic nucleus of atherosclerotic plaque, fibrous capsule depletion, and destabilisation of plaque resulting in rupture of arterial plaque. Therefore, the localisation of Lp-PLA2 in atherosclerotic lesions and their association with plaque instability supports a potential causal role for Lp-PLA2 in cardiovascular disease (CVD) [28].

A chronicle inflammatory process occurs at different stages of atherosclerosis [9], and the stages of atherosclerosis development are essential stages that require early detection to avoid CVD severity. Research shows that increased levels of Lp-PLA2 are linearly correlated with increased risk of CVD. However, it is known that Lp-PLA2 can be pro-inflammatory and anti-inflammatory at certain stages in the mechanism of CVD pathology. This research seeks to prove the anti-inflammatory role of Lp-PLA2. Therefore, the researchers sought to analyse the correlation between the monocyte population and Lp-PLA2 levels as two variables that can be used as markers for the early stages of atherogenesis, hopefully in time to prevent severe disease.

Materials and methods

Research design. This research was a cross-sectional study. The sample population of this research was chosen by total sampling among 86 people who attended health examination with risk factors of atherosclerosis based on American College of Cardiology (ACC) and American Heart Association (AHA) guidelines in Malang, East Java, Indonesia. We used human venous blood sampling to determine the concentration of Lp-PLA2 and circulating monocytes. Examination of blood profiles was conducted at the Saiful Anwar Central Hospital Laboratory, Malang. Measurement of Lp-PLA2 and monocyte concentrations was conducted in the Bioscience Laboratory, University Brawijaya, Malang.

Measurement of Lp-PLA2. Blood obtained from respondents was placed in an EDTA vacutainer containing anticoagulant and incubated for 10–20 minutes. Blood in the EDTA vacutainer was then centrifuged for 20 minutes at 2000–3000 rpm. Blood was then diluted with standard buffer solution. On the tube samples, 40 µL sample buffer solution was entered into the plate with 10 µL sample buffer solution consistent with dilution factor; they were then well shaken. The sample was then incubated for 30 minutes at 37°C. The concentrated buffer was diluted with water, and then 50 μL HRP-conjugated reagent was added to each tube, except for the control tube. The solution was incubated for 10 minutes and washed back. Fifty microliters of chromogen A and B solution were added into both tubes, shaken well, and incubated at 37°C for 15 minutes. Fifty microliters stop anti-dilution provisions were added into each tube to stop the reaction. The colour of the sample in the tube changed from blue to yellow. The optical absorption of the samples was read at 450 nm using a microtiter plate reader.

Measurement of monocytes. Monocytes were measured using the Hematology Analyzer method. The capillary tube is filled with blood. The specimen flows down the tube until it is near the dry end. The dry end was inserted vertically into the sealant and pushed to the tray’s bottom. The tube is twisted to remove it from the sealant and to prevent the sealing plug from being extracted. The sealed end of the tube was tapped on a flat surface to help ensure proper sealant contact in the tube. The prepared capillary tube was then wiped off. The capillary tube was put carefully in the centrifuge tube holder with the sealant end down. All tube positions were numbered on the rotor and can be used to record the position of each patient specimen. With the tube holders and hematocrit tubes in place, the lid was locked by firmly pressing down. Measurement of monocyte cells was based on the optical double-angle light scattering method (2…5°C).

Ethics clearance. The Medical Research Ethics Committee, Medical Faculty of the University of Brawijaya approved the research (Letter Number 277/EC/KEPK-S1-PD/11/2018).

Data analysis. Data analysis used the SPSS v.17 application with a confidence level of 95% (p < 0.05). Normality was tested with the Kolmogorov-Smirnov method, followed by one-way ANOVA, with post-hoc Tukey HSD. Correlations between variables were analysed using Pearson’s correlation test.

Results

Baseline Characteristics of Participants

The data below shows the characteristics of the 86 people based on age category, gender, body mass index (BMI), blood pressure, fasting blood sugar level, and lipid profile.

Based on Table 1, the data homogeneity is known to be different. To ensure that in this study, LP-PLA and Monocyte levels were not affected by other factors (age, sex, body mass index (BMI), blood pressure and fasting blood sugar), we analyzed using the Kruskal Wallis test. The data is homogeneous. Based on these tests, gender, age, body mass index (BMI), blood pressure, fasting blood sugar, and lipid profiles showed significance for monocytes. In Lp-PLA2, significant differences come from gender, age, body mass index (BMI), blood pressure and fasting blood sugar (p < 0.05).

 

Table 1. Baseline characteristics of the participants

Variable

Percentage

Lp-PLA2 (ng/mL)

Monocyte

Mean

p-value

Number of cells per 103/µL

Percentage

p-value

Gender

Male

56

0.105

0.032

0.287

7.26

0.042

Female

44

0.105

0.253

6.69

Age

30–49

28

0.103

0.025

0.281

7.18

0.034

50–69

59

0.107

0.265

6.89

70–89

13

0.103

0.283

7.14

Body mass index (kg/m2)

Underweight

7

0.107

0.024

0.287

7.00

0.036

Normal weight

40

0.105

0.269

6.78

Overweight

23

0.103

0.274

7.24

Obese Class I

17

0.107

0.250

7.16

Obese Class II

12

0.104

0.295

7.45

Obese Class III

1

0.104

0.420

8.90

Blood pressure (mmHg)

90/60–130/80

31

0.108

0.028

0.252

6.57

0.031

> 130/80

69

0.104

0.283

7.25

Fasting blood sugar (mg/dL)

< 70

52

0.106

0.039

0.268

6.75

0.045

70–99

20

0.105

0.264

7.46

> 99

28

0.104

0.282

7.89

Lipid profile (mg/dL)

Dyslipidemia

87

0.105

0.072

0.271

7.01

0.041

Non-dyslipidemia

13

0.107

0.274

6.97

 

The normality test for monocyte levels and Lp-PLA2 produced by Kolmogorov–Smirnov analysis resulted in p = 0.072 and p = 0.115, respectively, with a probability of p = 0.200 and p = 0.007. Therefore, it can be known that the monocyte data is declared normally distributed (p > 0.05); meanwhile, Lp-PLA2 is not.

Based on Spearman correlation analysis, the relationship between monocytes and Lp-PLA2 produced a probability value of 0.028. These results indicate that the probability is less than the level of significance (p < 0.05). Thus, it can be stated that there is a significant relationship between monocytes and Lp-PLA2. The positive correlation coefficient indicates that the relationship between monocyte and Lp-PLA2 concentration is directly proportional, meaning: higher monocyte levels matched higher Lp-PLA2 concentrations. The correlation coefficient of 0.789 is categorised as very strong. This result means that the relationship between monocyte levels and Lp-PLA2 concentration is significant and strong.

Discussion

Lp-PLA2 is secreted by inflammatory cells; one of them is monocytes. Lp-PLA2 binds with oxidised low-density lipoprotein (oxLDL) and breaks it into lysoPC and OxNEFA [28]. Lp-PLA2 inducing formation lipid mediator through hydrolysis of fatty acids. It has been shown that increase in the concentration of Lp-PLA2 in the blood indicates signs of plaque formation. It has also been shown that inhibiting the activity of Lp-PLA2 reduced the lesion of intimal and progressive atherosclerosis [18]. Research also mentions that an increase in inflammatory cells induces the concentration of Lp-PLA2 to increase on the atherosclerotic plaque [17, 26].

 

Table 2. Statistical characteristics of the variables

Variable

Min

Max

Mean

Standard deviation

Monocyte

Percentage (%)

4.2

11

6.99

1.49

Number (103/µL)

0.17

0.42

0.27

0.06

Concentration of Lp-PLA2

0.08

0.13

0.11

0.01

 

Lp-PLA2 is related to atherosclerosis risk factors such as gender, age, BMI, blood pressure, blood glucose level and lipid profile. Gender independently influences the exitance of Lp-PLA2: males have a high tendency towards high Lp-PLA2 concentrations compared to females [5, 31, 34]. This research also proves a significant relationship between gender and Lp-PLA2. A high concentration of Lp-PLA2 participants aged 62 years old and below indicates an increase in the risk factors of coronary heart disease; meanwhile, this is not applicable for those above 62 years old [11]. Research has also shown a significant relationship between age and Lp-PLA2. High BMI causes the concentration of Lp-PLA2 to increase [10]. This research also proves a significant relationship between BMI and Lp-PLA2. In the case of hypertension, blood pressure is directly proportional to the concentration of Lp-PLA2, where both increase together [15]. The research also proves a significant relationship between blood pressure and Lp-PLA2. Research has shown that diabetic retinopathy patients have a high concentration of Lp-PLA2. This finding indicates that high sugar content in the blood will induce an increase in Lp-PLA2 concentration [27]. The research also proves a significant relationship between fasting blood sugar and Lp-PLA2. Furthermore, patients with dyslipidemia undergo hypolipidemic medication for LDL level and Lp-PLA2 concentration in the blood [25]. But the research shows there is no significant relationship between lipid profile and Lp-PLA2.

This research shows that the concentration of Lp-PLA2 is high in the population with risk factors such as male, increase in age, non-smokers, underweight, normal blood pressure, low fasting blood sugar, and non-dyslipidemia. Meanwhile, the concentration of Lp-PLA2 is low in the population with risk factors such as female, young age group, smokers, increase in BMI, increase in blood pressure, increase in blood glucose level, and the condition of dyslipidemia. In addition, there was a significant relationship between Lp-PLA2 with gender, age, BMI, blood pressure and fasting blood sugar.

Based on the results received, the mean number and percentage of monocytes were high in: males; the age group of 30–49; smokers; obese class III; high blood pressure; high blood sugar level; and the population with dyslipidemia condition. Meanwhile, the mean number and percentage of monocyte were low in: the female age group of 50–69; non-smokers; normal BMI; normal blood pressure; the population with low blood sugar level; and the sample population with non-dyslipidemia condition. Based on previous research on monocytes, it is proven that risk factors can increase monocyte number and percentage. Although the difference in the result of monocyte received compared with previous research related to gender and number and percentage, females have a high number and percentage compared to males. Still, there was a significant relationship between gender and monocyte levels. There is a difference in the result received compared to previous research, which shows an increase in the age group lead to an increase in number and percentage, which proves the significant relationship between age and Lp-PLA2. Research shows BMI is directly proportional to the number and percentage cause both increases together, proving a significant relationship between BMI and monocytes. The increase in blood pressure and dyslipidemia will increase in number and percentages of monocytes. Both prove that it has a significant relationship with Lp-PLA2.

Monocytes in atherosclerotic lesions produce foam cells by breaking down oxLDL that contain lipid droplets. The accumulation of foam cells contributes to lipid storage and atherosclerotic plaque growth. The atherosclerotic plaque has a decreased ability to migrate the foam cells, leading to the resolution of inflammation and the development of other lesions into complex atherosclerotic plaques [22]. Some of the risk factors of atherosclerosis, such as gender, age, body mass index (BMI), blood pressure, blood glucose level, and lipid profile, seem related to the number and percentage of monocytes in the body.

Previous research shows a relationship between gender and monocyte number and percentage. Females have a higher number and percentage of monocyte than males, due to the estrogen hormone [24]. Research shows that a body mass index (BMI) in the obese category will increase monocyte number and percentage [23]. Also, high blood pressure causes the number and percentage of monocytes to increase [20]. Research shows that the number and percentage increase in patients with dyslipidemia is due to the LDL elevation [19, 30].

Monocytes also produce Lp-PLA2 [2]. Based on the research done, high activity of Lp-PLA2 is one of the independent factors of inflammation and risk factors of cardiovascular disease. Research proves that a high concentration of Lp-PLA2 causes an increase in the risk of stroke and coronary heart disease [6]. Meanwhile, monocytes produce oxidised LDL and HIF-1A, which will induce intercellular adhesion molecule (ICAM-1), vascular cell-1 adhesion molecule (VCAM-1), and enhance the endothelial adhesive properties in a proinflammatory-like effect [3]. Monocytes also produce Lp-PLA2 to break down oxLDL into lysoPC and OxNEFA. These particles will cause fibrous cap formation on the blood vessel [4]. Based on the results obtained from this research, there is a significant relationship between monocyte levels and Lp-PLA2. Furthermore, Lp-PLA2 is directly proportional to monocytes. Therefore, it can be seen that both can be used to detect risk in the early stages of atherogenesis, hopefully with appropriate therapy to prevent severe disease.

Conclusion

There is a significant relationship between monocytes and Lp-PLA2, and Lp-PLA2 is directly proportional to monocyte levels. This research proves that Lp-PLA2 tends to act as proinflammatory factor. Further research needs to be done to investigate Lp-PLA2 activity because it seems like the concentration and activity of Lp-PLA2 plays a role in formation of Lp-PLA2 products, such as LysoPC and oxNEFA, which play different roles in atherosclerogenesis.

Conflict of interest

The authors declare that there is no conflict of interest

Acknowledgements

The authors would thank the Ministry of Education and Culture, Republic of Indonesia, for research support and all participants contributing to this research.

×

About the authors

K. Kumboyono

University of Brawijaya

Email: publikasikoe@gmail.com
ORCID iD: 0000-0003-2124-8673

School of Nursing, Faculty of Health Sciences

Indonesia, 65145, Malang

Indah N. Chomsy

University of Brawijaya

Email: indahncys@gmail.com
ORCID iD: 0000-0002-1050-3571

Doctoral Program of Medical Science, Faculty of Medicine

Indonesia, 65145, Malang

Dinesh Vijayadas

University of Brawijaya

Email: vidst@icloud.com

Medical Study Program, Faculty of Medicine

Indonesia, 65145, Malang

Titin A Wihastuti

University of Brawijaya

Author for correspondence.
Email: titinwihastuti@gmail.com
ORCID iD: 0000-0001-6476-0541

School of Nursing, Faculty of Health Sciences

Indonesia, 65145, Malang

References

  1. Anzola L.K., Rivera J.N., Ramirez J.C., Signore A., Mut F. Molecular imaging of vulnerable coronary plaque with radiolabeled somatostatin receptors (SSTR). J. Clin. Med., 2021, vol. 10, no. 23: 5515. doi: 10.3390/jcm10235515
  2. Ashraf M.A., Nookala V. Biochemistry of platelet activating factor. In: StatPearlsTreasure Island (FL): StatPearls Publishing; 2021. URL: https://www.ncbi.nlm.nih.gov/books/NBK557392 (07.01.2022)
  3. Badimon L., Padró T., Vilahur G. Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. Eur. Heart J. Acute Cardiovasc. Care, 2012, vol. 1, no. 1, pp. 60–74. doi: 10.1177/2048872612441582
  4. Badimon L., Vilahur, G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med., 2014, vol. 276, no. 6, pp. 618–632. doi: 10.1111/joim.12296
  5. Brilakis E., Khera A., McGuire D., See R., Banerjee S., Murphy S., de Lemos J. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis, 2008, vol. 199, no. 1, pp. 110–115.
  6. Cai A., Li G., Chen J., Li X., Li L., Zhou Y. Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population. BMC Cardiovasc. Disord., 2015, vol. 15, no. 14. doi: 10.1186/s12872-015-0001-9
  7. Cardiovascular and and all-cause mortality over a 23-year period among Chinese with newly diagnosed diabetes in the Da Qing IGT and diabetes study. Diabetes Care, 2015, vol. 38, no. 7, pp. 1365–1371. doi: 10.2337/dc14-2498
  8. Coleman J.F. Robbins and Cotran's Pathologic Basis of Disease. Am. J. Surg. Pathol., 2010, vol. 34, no. 1: 132. doi: 10.1097/PAS.0b013e3181bc5f0f
  9. Colley K.J., Wolfert R.L., Cobble M.E. Lipoprotein associated phospholipase A2: Role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J., 2011, vol. 2, no. 1, pp. 27–38. doi: 10.1007/s13167-011-0063-4
  10. Da Silva I., Timm A. Damasceno N. Influence of obesity and cardiometabolic makers on lipoprotein-associated phospholipase A2 (LP-PLA2 ) activity in adolescents: the healthy young cross-sectional study. Lipids Health Dis., 2013, vol. 12, no. 1: 19. doi: 10.1186/1476-511X-12-19
  11. Franekvá J., Kettner J., Kubíček Z., Jabor A. The importance of age and statin therapy in the interpretation of LP-PLA2 in ACS patients, and relation to CRP. Physiol. Res., 2015, vol. 64, pp. 229–236. doi: 10.33549/physiolres.932765
  12. Gencer S., Evans B.R., van der Vorst E., Döring Y., Weber C. Inflammatory chemokines in atherosclerosis. Cells, 2021, vol. 10, no. 2: 226. doi: 10.3390/cells10020226
  13. Hilgendorf I., Swirski F.K., Robbins C.S. Monocyte fate in atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2015, vol. 35, no. 2, pp. 272–279. doi: 10.1161/ATVBAHA.114.303565
  14. Jaipersad A.S., Lip G.Y.H., Silverman S., Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J. Am. Coll. Cardiol., 2014, vol. 63, no. 1, pp. 1–11. doi: 10.1016/j.jacc.2013.09.019
  15. Kim M., Yoo H., Kim M., Ahn H., Park J., Lee S., Lee J. Associations among oxidative stress, Lp-PLA 2 activity and arterial stiffness according to blood pressure status at a 3.5-year follow-up in subjects with prehypertension. Atherosclerosis, 2017, vol. 257, pp. 179–185. doi: 10.1016/j.atherosclerosis.2017.01.006
  16. Libby P., DiCarli M., Weissleder R. The vascular biology of atherosclerosis and imaging targets. J. Nucl. Med., 2010, vol. 51, suppl. 1, pp. 33S–37S. doi: 10.2967/jnumed.109.069633
  17. Lin P., Ji H.H., Li Y.J., Guo S.D. Macrophage plasticity and atherosclerosis therapy. Front. Mol. Biosci., 2021, vol. 8: 679797. doi: 10.3389/fmolb.2021.679797
  18. Lind L., Simon T., Johansson L., Kotti S., Hansen T., Machecourt J., Ninio E., Tedgui A., Danchin N., Ahlström H., Mallat Z. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. Eur. Heart. J., 2012, vol. 33, no. 23, pp. 2946–2954.
  19. Linton M.R.F., Yancey P.G., Davies S.S., Jerome W.G., Linton E.F., Song W.L., Doran A.C., Vickers K.C. The role of lipids and lipoproteins in atherosclerosis. 2019. In: Endotext. Eds.: Feingold K.R., Anawalt B., Boyce A., Chrousos G., de Herder W.W., Dhatariya K., Dungan K., Hershman J.M., Hofland J., Kalra S., Kaltsas G., Koch C., Kopp P., Korbonits M., Kovacs C.S., Kuohung W., Laferrère B., Levy M., McGee E.A., McLachlan R., Morley J.E., New M., Purnell J., Sahay R., Singer F., Sperling M.A., Stratakis C.A., Trence D.L., Wilson D.P. South Dartmouth (MA): MDText.com, Inc.; 2000. URL: https://www.ncbi.nlm.nih.gov/books/NBK343489 (07.01.2022)
  20. Maekawa Y., Anzai T., Yoshikawa T., Asakura Y., Takahashi T., Ishikawa S., Ogawa S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction:a possible role for left ventricular remodeling. J. Am. Coll. Cardiol., 2002, vol. 39, no. 2, pp. 241–246. doi: 10.1016/S0735-1097(01)01721-1
  21. Moore K.J., Sheedy F.J., Fisher E.A. Macrophages in atherosclerosis: a dynamic balance. Nat. Rev. Immunol., 2013, vol. 13, no. 10, pp. 709–721. doi: 10.1038/nri3520
  22. Rafieian-Kopaei M., Setorki M., Doudi M., Baradaran A., Nasri H. Atherosclerosis: process, indicators, risk factors and new hopes. Int. J. Prev. Med., 2014, vol. 5, no. 8, pp. 927–946.
  23. Rogacev K.S., Ulrich C., Blömer L., Hornof F., Oste K., Ziegelin, M., Heine G.H. Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur. Heart. J., 2010, vol. 31, no. 3, pp. 369–376. doi: 10.1093/eurheartj/ehp308
  24. Roved J., Westerdahl H., Hasselquist D. Sex differences in immune responses: hormonal effects, antagonistic selection, and evolutionary consequences. Horm. Behav., 2017, vol. 88, pp. 95–105. doi: 10.1016/j.yhbeh.2016.11.017
  25. Saougos V., Tambaki A., Kalogirou M., Kostapanos M., Gazi I., Wolfert R., Elisaf M., Tselepis A. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler. Thromb. Vasc. Biol., 2007, vol. 27, no. 10, pp. 2236–2243. doi: 10.1161/ATVBAHA.107.147280
  26. Sertić J., Lovrić J., Bozina T., Skorić B. and Reiner Z. Does LP-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease? Acta Med. Croatica, 2010, vol. 64, no. 4, pp. 237–245.
  27. Siddiqui M., Kennedy G., Carr F., Doney A., Pearson E., Morris A., Johnson T., McLaughlin M., Williams R. Palmer C. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia, 2018, vol. 61, no. 6, pp. 1344–1353.
  28. Steen D.L., O’Donoghue M.L. LP-PLA2 Inhibitors for the reduction of cardiovascular events. Cardiol. Ther., 2013, vol. 2, no. 2, pp. 125–134. doi: 10.1007/s40119-013-0022-3
  29. Stone N.J., Robinson J.G., Lichtenstein A.H., Bairey Merz C.N., Blum C.B., Eckel R.H., Goldberg A.C., Gordon D., Levy D., Lloyd-Jones D.M., McBride P., Schwartz J.S., Shero S.T., Smith S.C. Jr., Watson K., Wilson P.W. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 2014, vol. 63, no. 25, part B, pp. 2889–2934. doi: 10.1016/j.jacc.2013.11.002
  30. Tolani S., Pagler T.A., Murphy A.J., Bochem A.E., Abramowicz S., Welch C., Nagareddy P.R., Holleran S., Hovingh G.K., Kuivenhoven J.A., Tall A.R. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis, 2013, vol. 229, no. 1, pp. 79–85. doi: 10.1016/j.atherosclerosis.2013.03.031
  31. Wang J., Jin M., Chen Y., Yuan Y., Ruan Y., Lu G. Lp-PLA2, a potential protector of lung cancer patients complicated with pleural effusion from lung diseases, proves effective for the diagnosis and pathological classification of lung cancer. Transl. Oncol., 2021,vol. 14, no. 4: 101030. doi: 10.1016/j.tranon.2021.101030
  32. Wihastuti T.A., Saka P.N.B., Sargowo D., Heriansyah T. The effect of darapladib administration to inflammation marker in early development of atherosclerosis: in vivo study for dyslipidemia model. Eur. Heart. J., 2019, vol. 21 (suppl. F), p. F51.
  33. World Health Organization (WHO). Cardiovascular Diseases (CVDs). 2017. URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (07.01.2022)
  34. Zhang F., Guo J., Yang F., Zhou Y. Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations. J. Clin. Lab. Anal., 2021, vol. 35, no. 3: e23691. doi: 10.1002/jcla.23691

Supplementary files

There are no supplementary files to display.


Copyright (c) 2022 Kumboyono K., Chomsy I.N., Vijayadas D., Wihastuti T.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 64788 от 02.02.2016.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies